Activaero and Chiesi to develop new treatment solution for cystic fibrosis patients

9th September 2013 (Last Updated September 9th, 2013 18:30)

Germany-based Activaero has entered into research collaboration with Italian pharmaceutical firm Chiesi Farmaceutici for the development of an effective solution to treat patients with cystic fibrosis (CF).

Germany-based Activaero has entered into research collaboration with Italian pharmaceutical firm Chiesi Farmaceutici for the development of an effective solution to treat patients with cystic fibrosis (CF).

Financial details of the deal have not been disclosed. As part of the deal, Activaero will offer its flow and volume regulated inhalation technology (FAVORITE) incorporated in a customised device solution to Chiesi.

The deal will see both companies jointly evaluate the potential of a novel drug device combination product using Activaero's FAVORITE inhalation approach and Chiesi's pharmaceutical agent to develop the treatment solution.

Chiesi vice-president and R&D director Paolo Chiesi said: "The FAVORITE inhalation approach is highly promising to achieve optimal lung deposition rates with lower drug doses and, ultimately, a better therapeutic outcome in the treatment of cystic fibrosis."

"The solution will provide optimum drug distribution across the complete lung, particularly the small airways, which are typically not accessible with standard nebuliser systems due to obstructions caused by scarred tissue and mucus in the lungs."

Chiesi has already secured approval and markets its proprietary inhaled tobramycin solution (Bramitob/Bethkis, 300mg/4ml UDV) directly or via partners in many countries worldwide, including the US.

The solution will provide optimum drug distribution across the complete lung, particularly the small airways, which are typically not accessible with standard nebuliser systems due to obstructions caused by scarred tissue and mucus in the lungs of cystic fibrosis patients.

The first part of the research work is expected to be completed by the end of 2013.

Activaero founder and CEO Gerhard Scheuch said the current programme can offer an improved treatment solution for cystic fibrosis, which is a detrimental disease with high unmet medical need.

"This exciting research collaboration represents further validation for our proprietary FAVORITE inhalation approach by one of the pioneers in the respiratory arena," Scheuch said.

According to the World Health Organization, cystic fibrosis is one of the most common genetic disorders amongst caucasians and is inherited recessively with an improved but still rather low life expectancy with a median age of currently 33.4 years.

The disease leads to chronic inflammations of the respiratory tract and also affects other organs, including the digestive tract, liver, sweat glands and reproductive organs.